Puma Bio Stock (NASDAQ:PBYI)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.95

52W Range

$2.23 - $7.73

50D Avg

$2.63

200D Avg

$4.04

Market Cap

$144.69M

Avg Vol (3M)

$309.73K

Beta

1.08

Div Yield

-

PBYI Company Profile


Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

185

IPO Date

Apr 24, 2012

Website

PBYI Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 20Dec 19Dec 18
License$2.50M$60.25M$50.50M
Royalty$5.68M$391.00K-
Product-$211.62M$200.49M

Fiscal year ends in Dec 23 | Currency in USD

PBYI Financial Summary


Dec 23Dec 22Dec 21
Revenue$235.64M$228.00M$253.20M
Operating Income$32.64M$23.70M$-8.90M
Net Income$21.59M$912.00K$-29.10M
EBITDA$32.64M$31.50M$1.70M
Basic EPS-$0.02$-0.72
Diluted EPS-$0.02$-0.72

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 01, 24 | 10:54 PM
Q1 24May 02, 24 | 12:00 AM
Q4 23Feb 29, 24 | 8:39 PM

Peer Comparison


TickerCompany
PTCTPTC Therapeutics, Inc.
ARVNArvinas, Inc.
RVMDRevolution Medicines, Inc. Warrant
IOVAIovance Biotherapeutics, Inc.
LRMRLarimar Therapeutics, Inc.
SRPTSarepta Therapeutics, Inc.
MGNXMacroGenics, Inc.
TSVT2seventy bio, Inc.
HRTXHeron Therapeutics, Inc.
VKTXViking Therapeutics, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
HEPAHepion Pharmaceuticals, Inc.
KURAKura Oncology, Inc.
CHRSCoherus BioSciences, Inc.
RAREUltragenyx Pharmaceutical Inc.
MDGLMadrigal Pharmaceuticals, Inc.